“The concept of ablating a portion of the prostate, rather than the entire gland, is gaining traction internationally and in the U.S.” - Dr. Mark Carol
Charlotte, NC (PRWEB) March 17, 2016
SonaCare Medical, global leader in high-intensity focused ultrasound (HIFU) ablation devices, announces that the first Sonablate procedure, performed with the newly integrated MIM Symphony fusion software, was completed by Dr. Richard Hindley of Nuada Group on March 9th, 2016. SonaCare Medical continues to be the only open architecture HIFU system to be compatible with leading fusion software platforms, allowing seamless integration with a physician’s targeted biopsy system of choice.
Dr. Hindley used SonaFuse-MIM, a version of the MIM Symphony fusion software integrated into the Sonablate system, to fuse a previously obtained magnetic resonance image with live Sonablate ultrasound images collected during the HIFU procedure. This allowed him to transfer regions-of-interest that had been previously identified on the MRI to the images generated during the procedure, making for a more precisely targeted ablation.
Delivered under the observation of Dr. Hashim Ahmed, Dr. Richard Hindley’s procedure represents a significant milestone for both Nuada Group as well as SonaCare Medical. “Nuada Group has been committed to the success of HIFU for the ablation of prostate tissue for several years,” comments CEO of Nuada Group, Brian Lynch. “We are excited to see more patients benefiting from it as awareness and acceptance of the technology, expertise and effectiveness grows. Nuada Group has invested in world-class resources to lead this growth in the UK, which include Dr. Clare Allen, Uro-radiologist who has become an expert in contouring MR images using MIM software; Dr. Richard Hindley, who has championed the application of fusion biopsy technology, and Dr. Hashim Ahmed, who has led the groundbreaking research on HIFU for prostate patients over the last 5 years and who has been largely responsible for demonstrating its effectiveness.”
SonaCare Medical felt honored to work with Nuada and, in particular, Drs. Hash Ahmed and Richard Hindley, two of the global leaders in focal ablation/HIFU, to support the successful launch of this highly anticipated integration of MIM software into Sonablate technology. Onsite technical representative for SonaCare Medical, John Strait, reports, “The case went very smoothly, the integration performed exactly as expected, and everyone was pleased with the addition of MIM fusion.”
“The concept of ablating a portion of the prostate, rather than the entire gland, is gaining traction internationally and in the U.S.,” states SonaCare Medical CEO, Dr. Mark Carol. “Focal ablation requires precise knowledge of the targeted region within the gland which can be guided most effectively by preoperative localization on MRI images. We are delighted that the excellent MIM fusion software, which supports fusion of MRI images and intraoperative ultrasound images, is now implemented for use with Sonablate, and that the first procedure with this combined technology was delivered by Nuada Group, an organization that has taken an international leadership role in the application of fusion technologies for diagnosis of prostate disease and Sonablate for the ablation of targeted prostate tissue.”
Sonablate® is the first device to receive regulatory authorization from the FDA for the focused ultrasound ablation of prostate tissue. Since its introduction over 15 years ago, Sonablate® technology has been used around the world on nearly 15,000 patients in over 30 countries, including approximately 4,000 U.S. men who have had this procedure performed outside the U.S.
About SonaCare Medical, LLC
SonaCare Medical is a world leader in minimally invasive focused ultrasound (HIFU) technologies. SonaCare Medical is committed to developing focused ultrasound related technologies that support precise and innovative procedures for the treatment of a range of medical conditions. SonaCare Medical, with its subsidiary Focus Surgery, Inc., designs and manufactures medical devices, including the following: Sonablate®, which has 510(K) clearance in the U.S. under a De Novo regulatory classification; Sonablate® 500, which has CE Marking and has obtained regulatory authorization in more than 49 countries outside the U.S.; Sonatherm® laparoscopic HIFU surgical ablation system, which has 510(K) clearance in the U.S., has CE Marking and has obtained regulatory authorization in more than 30 countries outside the U.S.
For additional information, visit http://www.SonaCareMedical.com
SonaCare Medical, LLC
Erica Griffith (704) 936-1834, EricaGriffith(at)SonaCareMedical.com
Forward Looking Statements.
The Company's forward-looking statements are based on management's current expectations and assumptions regarding the Company's business and performance, the economy and other future conditions and forecasts of future events, circumstances and results. As with any projection or forecast, forward-looking statements are inherently susceptible to uncertainty and changes in circumstances. The Company's actual results may vary materially from those expressed or implied in its forward-looking statements. Any forward-looking statement made by the Company speaks only as of the date on which it is made. The Company is under no obligation to, and expressly disclaims any obligation to, update or alter its forward-looking statements, whether as a result of new information, subsequent events or other factors.